| High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center M Bektaş, S Yüce, M Ay, MH Uyar, ME Önder, Mİ Kılıç Inflammopharmacology 31 (2), 787-797, 2023 | 8 | 2023 |
| Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study R Çakmak, S Yüce, M Ay, MH Uyar, Mİ Kılıç, M Bektaş Scientific Reports 14 (1), 12369, 2024 | 1 | 2024 |
| Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study M Bektaş, M Ay, MH Uyar, Mİ Kılıç International Immunopharmacology 129, 111586, 2024 | 1 | 2024 |
| AB0087 INTRAVENOUS HIGH-DOSE ANAKINRA DROPS VENOUS THROMBOSIS AND MYOCARDIAL INFARCTION IN SEVERE AND CRITICAL COVID-19 PATIENTS: A PROPENSITY SCORE MATCHED STUDY M Bektaş, M Ay, M Uyar, Mİ Kiliç Annals of the Rheumatic Diseases 83, 1276, 2024 | | 2024 |
| Intravenous High-dose Anakinra Drops Venous Thrombosis and Myocardial Infarction in Severe and Critical COVID-19 Patients: A Propensity Score Matched Study R Çakmak, S Yüce, M Ay, MH Uyar, Mİ Kılıç, M Bektaş | | 2024 |
| POS0555 HIGH DOSE INTRAVENOUS ANAKINRA TREATMENT IS SAFE AND EFFECTIVE IN SEVERE AND CRITICAL COVID-19 PATIENTS: A PROPENSITY SCORE MATCHED STUDY IN A SINGLE CENTER M Bektaş, S Yüce, M Ay, M Uyar, M Önder, Mİ Kiliç Annals of the Rheumatic Diseases 82, 544, 2023 | | 2023 |
| High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center M Ay, S YÜCE, M BEKTAŞ, MI Kilic, MH Uyar | | 2023 |